Meropenem Noridem Enterprises (Meropenem Anhydrous)

Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, which blocks the final cross‑linking step of peptidoglycan formation. This leads to a weakened cell wall, osmotic instability and ultimately bacterial lysis. Its resistance to most β‑lactamases expands its activity against many resistant pathogens.

The specific dose of Meropenem is determined by the prescribing clinician based on the infection type, severity, patient weight, renal function and local guidelines. Dosing regimens are individualized and should follow the prescriber’s order and institutional protocols.

Data on Meropenem use in pregnancy and lactation are limited. It should be used only when the potential benefit justifies any potential risk to the fetus or infant. Clinicians should assess each case individually and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details (including cold‑chain if needed) and assists with import documentation.

Meropenem offers a broad spectrum similar to other carbapenems such as imipenem‑cilastatin and ertapenem, but it has enhanced stability against many β‑lactamases and a slightly broader Gram‑negative coverage. Compared with non‑carbapenem β‑lactams, it provides more reliable activity against multidrug‑resistant organisms, making it a preferred option for high‑risk hospital infections.

Meropenem for injection should be stored refrigerated at 2‑8 °C (36‑46 °F). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Once reconstituted, follow the manufacturer’s stability guidelines and use within the recommended time frame.

Meropenem is given intravenously. The powder is reconstituted with a compatible diluent, then diluted in an appropriate infusion fluid. It is administered as a short infusion (typically 15‑30 minutes) or as a prolonged infusion, according to the prescriber’s instructions and the patient’s renal function.

The most serious adverse events include seizures, especially in patients with renal impairment or pre‑existing CNS disorders, severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome, and Clostridioides difficile‑associated colitis, which can be life‑threatening.

Meropenem is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is advised for individuals with severe renal impairment who have not had dose adjustments, and for patients with a history of seizures unless the benefits outweigh the risks.